| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.04 |
| mRNA | AZD6482 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.04 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.04 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | KIN001-244 | GDSC1000 | pan-cancer | AAC | -0.067 | 0.04 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.04 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.065 | 0.05 |
| mRNA | SCH-79797 | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.05 |